Phase 1 Study to Assess the Effects of EVP-6124 on the QT/QTc Interval in Healthy Subjects
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of EVP-6124 at therapeutic and
supratherapeutic concentrations on cardiac repolarization in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
FORUM Pharmaceuticals Inc
Collaborator:
Quintiles, Inc.
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination